A
Editas Medicine, a startup that wants to enable “molecular surgery”  to cut out bad genes before they can manifest themselves, has $43 million in Series A funding from Polaris Partners, Flagship Ventures and Third Rock Ventures.  Co-founder Dr. J.Keith Joung, who is also director of molcular pathology at Mass General Hospital, told The Boston Globe that the idea is to “make changes to DNA … if there’s a defect, you can fix it; if there’s a missing piece you can put the missing piece in.”
Story posted at: boston.com
Subscriber Content
?
Subscriber content comes from Gigaom Research, bridging the gap between breaking news and long-tail research. Visit any of our reports to learn more and subscribe.
